VITAL is happy to announce a new non-dilutive funding opportunity supporting advancements in long-acting monoclonal antibody and/or nucleic acid-based platforms for pre-exposure prophylaxis (PrEP) for seasonal and pandemic influenza and other respiratory viruses. Start2 and BARDA established VITAL – a BARDA Accelerator Network (BAN) hub providing non-dilutive funding and accelerator program support for innovations in vaccines and therapeutics targeting infectious diseases.
VITAL seeks innovations that improve delivery, biodistribution, half-life extension, and durability of vaccines and therapeutics. VITAL now has a <link https: deu01.safelinks.protection.outlook.com>NEW FUNDING SOLICITATION for up to $7.5M over 3 years. The solicitation is OPEN NOW, and accepting applications from academic innovators and startups from Europe, the U.S., and Asia! More detailed information is found on VITAL’s website <link https: deu01.safelinks.protection.outlook.com>here.
This new solicitation supports advancements of monoclonal antibody (mAbs) and nucleic acid platforms for pre-exposure prophylaxis (PrEP) for influenza and other respiratory viruses. More detailed information about this PrEP funding opportunity is provided on the VITAL website and in this document <link file:41602 download>“VITAL prep funding solicitation autumn 2024 – final.pdf”. Additionally, information about VITAL in general and all the funding and program opportunities we provide is found in another document: “VITAL overview oct 2024.pdf”.
VITAL, managed by Start2 Group (a German Accelerator program), is a new BARDA Accelerator Network (BAN) hub providing non-dilutive funding and accelerator program support for innovations in vaccines and therapeutics targeting infectious diseases.